---
title: "Aligos Therapeutics ernennt Nikhil Aneja zum Principal Accounting Officer"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/274867162.md"
datetime: "2026-02-04T21:10:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274867162.md)
  - [en](https://longbridge.com/en/news/274867162.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274867162.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/274867162.md) | [English](https://longbridge.com/en/news/274867162.md)


# Aligos Therapeutics ernennt Nikhil Aneja zum Principal Accounting Officer

Aligos Therapeutics Inc. hat bekannt gegeben, dass Nikhil Aneja ab sofort als Principal Accounting Officer des Unternehmens ernannt wurde. Er folgt auf Lesley Ann Calhoun, die weiterhin als Executive Vice President, Chief Operating Officer und Chief Financial Officer tätig ist. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aligos Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-037558), on February 04, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### 相關股票

- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-HK/quote/PBE.US.md)
- [VG Health (VHT.US)](https://longbridge.com/zh-HK/quote/VHT.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-HK/quote/IBB.US.md)
- [Aligos Therapeutics (ALGS.US)](https://longbridge.com/zh-HK/quote/ALGS.US.md)
- [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-HK/quote/FBT.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-HK/quote/BBH.US.md)
- [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-HK/quote/XLV.US.md)
- [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-HK/quote/BIB.US.md)
- [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-HK/quote/XBI.US.md)
- [iShares US Pharma (IHE.US)](https://longbridge.com/zh-HK/quote/IHE.US.md)
- [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/zh-HK/quote/IBBQ.US.md)
- [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-HK/quote/ARKG.US.md)

## 相關資訊與研究

- [Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study | INTS Stock News](https://longbridge.com/zh-HK/news/278874097.md)
- [Vertex's kidney disease drug meets main goal in late-stage trial](https://longbridge.com/zh-HK/news/278442392.md)
- [Acurx Pharmaceuticals Q4 net loss narrows on lower R&D spend](https://longbridge.com/zh-HK/news/279032442.md)
- [Galecto Rebrands as Damora Therapeutics with New Ticker](https://longbridge.com/zh-HK/news/278556054.md)
- [Citius Highlights Positive LYMPHIR Phase 1 Gynecologic Cancer Data](https://longbridge.com/zh-HK/news/278566951.md)